Drug intelligence / Profile preview

PRX202

Development stage: Preclinical
Lead developer: Prazer Therapeutics
Modality: Small Molecules

Overview

PRX202 is a small molecule drug developed by Praser Therapeutics. It acts as an inhibitor of the sodium taurocholate co-transporting polypeptide (NTCP), also known as the sodium/bile acid cotransporter. The primary therapeutic area for PRX202 is infectious diseases and digestive system disorders, with its main active indication being hepatitis B. As of May 2025, the highest global R&D status for PRX202 is preclinical[1].

Targets

NTCP (Na+-taurocholate cotransporting polypeptide)

Beyond the preview

Go deeper on PRX202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRX202.

Explore the full profile